At this year’s virtual Science Day, Moderna will present new platform science and preclinical research, including:
Engineering mRNA and Proteins to Improve Therapeutic Properties – advantage of mRNA medicines over small molecule drugs is the ease of engineering their properties to achieve desired pharmacology. New research will be presented on efforts to engineer both mRNAs and encoded proteins to improve and extend therapeutic effect. At Science Day, Moderna will present a protein engineering workflow by which it has engineered a Moderna T7 RNA polymerase (MT7) that does not produce dsRNA impurities.
Optimizing Lipid Nanoparticle Technology – the Company will present new research in delivery science to optimize its lipid nanoparticles (LNPs). The presentations will highlight a novel squaramide-based ionizable lipid designed to enhance the interactions between the lipid and mRNA. Preclinical data from new LNPs incorporating this novel ionizable lipid show improved protein expression after IV administration, including repeat dosing, and efficient delivery to the liver, as compared to current state-of-the-art Moderna proprietary LNPs.
Collaborating on an HIV Vaccine – research conducted through Moderna’s ongoing collaborations with International Aids Vaccine Initiative (IAVI), National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation, will be showcased. This research seeks to deliver an engineered HIV immunogen using Moderna’s mRNA platform that allows for a faster, more flexible approach to rapid iterative vaccine design and clinical testing.
across Moderna’s pipeline